January 15th, 2008
The U.S. Food and Drug Administration (FDA) has approved a test that helps in assessing the risk of tumor recurrence and long-term survival for patients with relatively high-risk breast cancer. The TOP2A FISH pharmDx is the first approved device to test for the TOP2A (topoisomerase 2 alpha) gene in cancer patients.
The TOP2A gene plays a […]
By Elaine -- 0 comments
December 15th, 2007
Further to my articles on FDA approved Mammaprint, Agendia BV, world leader in the rapidly evolving field of molecular diagnostics, announced that an independent international consortium has demonstrated the prognostic power of its MammaPrint breast cancer prognosis test in patients who have 1-3 positive lymph nodes. The data show that MammaPrint can accurately identify a low […]
By Elaine -- 0 comments
October 30th, 2007
Following my article on latest prognostic tests for breast cancer, Dutch firm Agendia BV are leading the field again! Their Mammaprint® test is the first microarray to gain FDA approval and now they have won a prestigious award for innovation in the field of breast cancer.
The 2007 Frost & SullivanEuropean Product Innovation Award in the field of biomarker-based […]
By Elaine -- 0 comments
Recent Comments